Supplementary material 1. Search Strategy

1 Joint Capsule/
2 Capsula Articularis.mp.
3 Synovial Capsule.mp.
4 articular Capsule.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
5 1 or 2 or 3 or 4
6 Rotator Cuff/
7 Teres Minor.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
8 Subscapularis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
9 infraspinatus.mp. 1965
10 Supraspinatus.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
11 6 or 7 or 8 or 9 or 10
12 *Cartilage, Articular/
13 Articular Cartilages.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
14 Hyaline Cartilage/
15 Hyaline Cartilag$ (ti,ab)
16 *Synovial Membrane/
17 synovial membrane$ (ti,ab)
18 synovium (ti,ab)
19 12 or 13 or 14 or 15 or 16 or 17 or 18
20 *Joint Diseases/
21 joint disease$ (ti,ab)
22 arthrosis (ti,ab)
23 arthropat$ (ti,ab)
24 *arthritis/
25 arthrit$ (ti,ab)
26 *synovitis/
27 Synovial Hypertrop$ (ti,ab)
28 synovial thick$ (ti,ab)
29 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30 BURSITIS/
31 bursit$ (ti,ab)
32 capsulit$ (ti,ab)
33 "frozen shoulder$" (ti,ab)
34 "adhesive capsulit$" (ti,ab)
35 30 or 31 or 32 or 33 or 34
36 Injections, Intra-Articular/
37 intraarticular injection$ (ti,ab)
38 intra-Articular injection$ (ti,ab)
39 VISCOSUPPLEMENTATION/
40 "Viscosupplementation" (ti,ab)
41 "Visco-supplementation" (ti,ab)
42 ("Orthopedic Procedure$" not surg$) (ti,ab)
43 *Hyaluronic Acid/
44 Hyaluronic Acid (ti,ab)
45 "Hyaluron$" (ti,ab)
46 "Amo Vitrax".mp.
47 Vitrax, Amo.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
48 "Bilon".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword 25 heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

49 "hyvisc".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword 1 heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

50 "luronit".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword 1 heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

51 "Amvisc".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

52 "GLYCOSAMINOGLYCAN$\" (ti,ab)

53 "Mucopolysaccharid$" (ti,ab)

54 TRIAMCINOLONE/

55 "Volon".mp.

56 "Aristocort".mp.

57 Triamcinolone Acetonide/

58 "Tricort-40".mp.

59 "Tricort 40".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

60 "Kenalog 40".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

61 "Azmacort".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

62 "Kenacort A".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

63 "Triamcinolone hexacetone/d.mp. 346

64 "Aristospan".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

65 "Mesenchymal Stromal Cel$/dg, de, and, im, me, pa, ph, re [Diagnostic Imaging, Drug Effects, Enzymology, Immunology, Metabolism, Pathology, Physiology, Radiation Effects]

66 Cel$, Mesenchymal Stromal (ti,ab)

67 Stromal Cel$, Mesenchymal (ti,ab)

68 Mesenchymal Stem Cell.mp.

69 "Mesenchymal Stem Cel$/s (ti,ab)

70 limit 69 to "therapy (best balance of sensitivity and specificity)"

71 "Mesenchymal Progenitor Cel$/s (ti,ab)

72 limit 71 to "therapy (best balance of sensitivity and specificity)"

73 "Mesenchymal Stromal Cells, Multipotent” (ti,ab)

74 "Multipotent Bone Marrow Stromal Cel$/s (ti,ab)

75 "Bone Marrow Stromal Cel$/s, Multipotent” (ti,ab)

76 "Wharto$ Jelly Cel$/s (ti,ab)

"Cel$, Wharto$ Jelly”.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

77 "Stem Cel$/s, Multipotent” (ti,ab)

78 "Multipotent Stem Cel$/s” (ti,ab)

79 limit 78 to "therapy (best balance of sensitivity and specificity)"

80 "Stem Cel$/s, Multipotent” (ti,ab)

81 Platelet-Rich Plasma/

82 "Plasma, Platelet-Rich” (ti,ab)

83 "Platelet Rich Plasma” (ti,ab)

84 "Blood Platelets/

85 limit 84 to "therapy (best balance of sensitivity and specificity)"

86 limit 84 to "therapy (best balance of sensitivity and specificity)"

87 "Blood Platelets” (ti,ab)

88 limit 87 to "therapy (maximizes specificity)"

89 "Platelets, Blood” (ti,ab)
187 *Cocaine/ad, ae, aa, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
188 limit 187 to “therapy (best balance of sensitivity and specificity)”
189 *Dibucaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
190 *Diphenhydramine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
191 *Ethyl Chloride/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
192 *Etidocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
193 *Lidocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
194 *Mepivacaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
195 *Prilocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
196 *Procaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
197 *Propoxycaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
198 *Tetracaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
199 *Tetrodotoxin/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
200 *Trimecaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
201 175 or 177 or 178 or 179 or 180 or 181 or 182 or 183 or 184 or 185 or 186 or 188 or 189 or 190 or 191 or 192 or 193 or 194 or 195 or 196 or 197 or 198 or 199 or 200
202 *Analgesics, Opioid/ad, ae, ag, ai, bl, ch, cl, im, me, pk, pd, po, tu, to, ur [Administration & Dosage, Adverse Effects, Agonists, Antagonists & Inhibitors, Blood, Chemistry, Classification, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity, Urine]
203 limit 202 to “therapy (best balance of sensitivity and specificity)”
204 *Opioid Analgesics” (ti,ab)
205 “Partial Opioid AgonistS” (ti,ab)
206 “Opioid Agonists, Partial” (ti,ab)
207 “Opioids” (ti,ab)
208 limit 207 to “therapy (best balance of sensitivity and specificity)”
209 “Opioid Partial Agonists” (ti,ab)
210 (“Agonists” and “Opioid Partial”) (ti,ab)
211 (“Partial Agonists” and “Opioid”) (ti,ab)
212 “Full Opioid Agonists” (ti,ab)
213 (“Agonists” and “Full Opioid”) (ti,ab)
214 (“Opioid Agonists” and “Full”) (ti,ab)
215 “Opioid Full Agonists” (ti,ab)
216 (“Agonists” and “Opioid Full”) (ti,ab)
217 (“Full Agonists” and “Opioid”) (ti,ab)
218 “Opioid Mixed Agonist-Antagonists” (ti,ab)
219 (“Agonist-Antagonists” and “Opioid Mixed”) (ti,ab)
220 (“Mixed Agonist-Antagonists” and “Opioid”) (ti,ab)
221 "Opioid Mixed Agonist Antagonists" (ti,ab)
222 *Alfentanil/ad, ae, aa, ai, bl, me, pk, pd, tu, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]
223 *Alphaprodine/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]
224 *Buprenorphine/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]
225 *Buprenorphine, Naloxone Drug Combination/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]
226 *BUPRENORPHINE, NALOXONE DRUG COMBINATION/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
227 *Butorphanol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
228 *Codeine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
229 *Dextromoramide/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
230 *Dextropropoxyphene/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
231 *Dihydromorphone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
232 *Diphenoxylate/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
233 *Ethylketocyclazocine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
234 *Ethyldihydromorphone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
235 *Etorphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
236 *Fentanyl/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
237 *Heroin/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
238 limit 237 to "therapy (maximizes specificity)"
239 *Hydrocodone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
240 *Hydromorphone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
241 *Levorphanol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
242 *Levimethadyl Acetate/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
243 *Levonorgestrel/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
244 *Methadone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
245 *Methadyl Acetate/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
246 *Morphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
247 limit 246 to "therapy (maximizes specificity)"
248 *Naltrexone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
249 *Opiate Alkaloids/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
250 *Opium/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
251 *Oxycodone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
252 *Oxymorphone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
253 *Pentazocine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
254 *Phenoperidine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
255 *Pirintranamide/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
256 *Promedol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
257 *Sufentanil/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
258 *Tilidine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]
259 *Tramadol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

261 limit 259 to “therapy (best balance of sensitivity and specificity)”

262 *MORPHINE/ad, ae, ag, ai, bl, ch, im, ip, me, pk, pd, po, tu, th, to [Administration & Dosage, Adverse Effects, Agonists, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Isolation & Purification, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Therapy, Toxicity]

264 (Receptor$ and Opioid$ and mu) (ti,ab)
265 limit 264 to “therapy (maximizes specificity)”

266 (“Opioid Receptors” and “mu”) (ti,ab)
267 limit 266 to “therapy (maximizes specificity)”

268 “mu Opioid Receptors” (ti,ab)
269 (“Receptors” and “mu Opioid”) (ti,ab)
270 “mu Receptor” (ti,ab)
271 (Receptor$ and mu) (ti,ab)
272 “mu Receptors” (ti,ab)
273 “mu Opioid Receptors” (ti,ab)
274 (Opioid Receptor “and” “mu”) (ti,ab)
275 (“Receptor” and “mu Opioid”) (ti,ab)
276 (Receptor$ “and” “Morphine”) (ti,ab)
277 “Morphine Receptor$” (ti,ab)
278 morphine-like compounds.mp.

280 non peptide morphine like compounds.mp.

282 203 or 204 or 205 or 206 or 208 or 209 or 210 or 211 or 212 or 213 or 214 or 215 or 216 or 217 or 218 or 219 or 220 or 221 or 222 or 223 or 224 or 225 or 226 or 227 or 228 or 229 or 230 or 231 or 232 or 233 or 234 or 235 or 236 or 238 or 239 or 240 or 241 or 242 or 243 or 244 or 245 or 247 or 248 or 249 or 250 or 251 or 252 or 253 or 254 or 255 or 256 or 257 or 258 or 260 or 261 or 262 or 263 or 265 or 267 or 268 or 269 or 270 or 272 or 273 or 274 or 275 or 277 or 278 or 279 or 280 or 281

283 “Antirheumatic Agents/ad, ae, ai, bl, ch, im, me, pk, pd, po, tu, to [Administration & Dosage, Adverse Effects, Antagonists & 812 Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity]”

284 limit 283 to “therapy (maximizes specificity)”

285 “Anti-Rheumatic Drugs” (ti,ab)
286 “Anti-Rheumatic Drugs” (ti,ab)
287 “Anti-Rheumatic Agents” (ti,ab)
288 “Anti Rheumatic Agents” (ti,ab)
289 (“Anti rheumatic Drugs” and “Disease-Modifying”) (ti,ab)
290 (“Anti rheumatic Drugs” and “Disease Modifying”) (ti,ab)
291 “DMARD” (ti,ab)
292 “Disease-Modifying Antirheumatic Drugs” (ti,ab)
293 (“Anti-Rheumatic Agents” and “Non-steroidal”) (ti,ab)
294 (“Anti Rheumatic Agents” and “Non-steroidal”) (ti,ab)
295 “Non-steroidal Anti-Rheumatic Agents” (ti,ab)
296 *ALLOPURINOL/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
297 *Abatacept/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
355 *Sulindac/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
356 *Salicylic acid/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
357 *Tolmetin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
358 *Suprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
359 *Zoxazolamine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
360 "bucillamine" (ti,ab)
361 "dexketoprofen trometamol" (ti,ab)
362 etoricoxib (ti,ab)
363 "leflunomide" (ti,ab)
364 "meloxicam" (ti,ab)
365 *Immunosuppressive Agents/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]
366 ("Agents" and "Immunosuppressive") (ti,ab)
367 limit 365 to "therapy (best balance of sensitivity and specificity)"
368 "Immunosuppressants" (ti,ab) 94529
369 limit 368 to "therapy (best balance of sensitivity and specificity)"
370 "Monoclonal Antibody cA2" (ti,ab)
371 ("cA2" and "Monoclonal Antibody") (ti,ab)
372 Remicade (ti,ab)
373 *Antibodies, Monoclonal/ad, ae, an, ai, bl, ch, de, im, me, pk, pd, ph, po, tu, to [Administration & Dosage, Adverse Effects, Analysis, Antagonists & Inhibitors, Blood, Chemistry, Drug Effects, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Therapeutic Use, Toxicity]
374 limit 373 to "therapy (best balance of sensitivity and specificity)"
375 "Monoclonal Antibodies" (ti,ab) 94529
376 limit 375 to "therapy (best balance of sensitivity and specificity)"
377 *Tumor Necrosis Factor-alpha/ad, ae, ag, ai, bl, ch, de, im, me, pk, pd, ph, po, re, tu, to [Administration & Dosage, Adverse Effects, Agonists, Analysis, Antagonists & Inhibitors, Blood, Chemistry, Drug Effects, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Therapeutic Use, Toxicity]
378 limit 377 to "therapy (best balance of sensitivity and specificity)"
379 "Tumor Necrosis Factor alpha" (ti,ab)
380 "Cachectin" (ti,ab)
381 ("Cachectin" and "Tumor Necrosis Factor") (ti,ab)
382 "Cachectin Tumor Necrosis Factor" (ti,ab)
383 "Tumor Necrosis Factor Ligand Superfamily Member 2" (ti,ab)
384 "TNFalpha" (ti,ab)
385 limit 384 to "therapy (maximizes specificity)"
386 "CT-P13 " (ti,ab)
387 ("Antibodies" and "Monoclonal" and "Humanized") (ti,ab)
388 ("Antibodies" and "Humanized") (ti,ab)
389 "Humanized Antibodies" (ti,ab)
390 ("Antibodies" and "Monoclonal" and "Murine-Derived") (ti,ab)
391 ("Murine-Derived" and "Monoclonal" and "Antibodies") (ti,ab)
392 ("Antibodies" and "Murine-Derived" and "Monoclonal") (ti,ab)
393 ("Monoclonal Antibodies" and "Murine-Derived") (ti,ab)
394 "D2E7 Antibody" (ti,ab)
395 ("Antibody" and "D2E7") (ti,ab)
396 Humira (ti,ab)
397 ("Receptors" AND "Tumor Necrosis Factor") (ti,ab)
398 limit 397 to "therapy (best balance of sensitivity and specificity)"
399 ("Receptors" and "Cachectin") (ti,ab)
400 "Tumor Necrosis Factor Receptors" (ti,ab)
401 "TNF Receptor" (ti,ab)
402 limit 401 to "therapy (best balance of sensitivity and specificity)"
403 "Tumor Necrosis Factor Receptor" (ti,ab)
404 "Cachectin Receptors" (ti,ab)
405 ("Receptors" and "TNF") (ti,ab)
406 limit 405 to "therapy (maximizes specificity)"
407 284 or 285 or 286 or 287 or 288 or 289 or 290 or 291 or 292 or 293 or 294 or 295 or 296 or 297 or 298 or 299 or 300 or 301 or 302 or 303 or 304 or 305 or 306 or 307 or 308 or 309 or 310 or 311 or 312 or 313 or 314 or 315 or 316 or 317 or 318 or 319 or 320 or 321 or 322 or 323 or 324 or 325 or 326 or 327 or 328 or 329 or 330 or 331 or 332 or 333 or 334 or 335 or 336 or 337 or 338 or 339 or 340 or 341 or 342 or 343 or 344 or 345 or 346 or 347 or 348 or 349 or 350 or 351 or 352 or 353 or 354 or 355 or 356 or 357 or 259132 358 or 359 or 360 or 361 or 362 or 363 or 364 or 365 or 366 or 367 or 368 or 369 or 370 or 371 or 372 or 374 or 376 or 378 or 379 or 380 or 381 or 382 or 383 or 385 or 386 or 387 or 388 or 389 or 390 or 391 or 392 or 393 or 394 or 395 or 396 or 398 or 399 or 400 or 401 or 402 or 403 or 404 or 405 or 406

408 "Synovial Hypertrophy" (ti,ab)
409 "Radiosynoviorthesis" (ti,ab)
410 "Radiosynovectomy" (ti,ab)
411 "169Er-citrate" (ti,ab)
412 "Intraarticular Morphine" (ti,ab)
413 "Intraarticular opioids" (ti,ab)
414 "Intraarticular anesthetics" (ti,ab)
415 "Intraarticular glucocorticoids" (ti,ab)
416 "Dry Needling" (ti,ab)
417 Meta-Analysis as Topic/
418 meta analy$.tw.
419 Meta-Analysis/
420 (systematic adj (review$1 or overview$1)).tw.
421 exp Review Literature as Topic/
422 metaanaly$.tw.
423 cochrane.ab.
424 embase.ab.
425 (psychlit or psyclit).ab.
426 (psychinfo or psycinfo).ab.
427 (cinahl or cinhal).ab.
428 science citation index.ab.
429 bids.ab.
430 417 or 418 or 419 or 420 or 421 or 422
431 cancerlit.ab.
432 423 or 424 or 425 or 426 or 427 or 428 or 429 or 431
433 reference list$.ab.
434 bibliograph$.ab.
435 hand-search$.ab.
436 relevant journals.ab.
437 manual search$.ab.
438 433 or 434 or 435 or 436 or 437
439 selection criteria.ab.
440 data extraction.ab.
441 444 or 445 or 446 or 449
442 Review/
443 441 or 442
444 Comment/
445 Letter/
446 Editorial/
447 animal/
448 human/
449 447 not (447 and 448)
450 444 or 445 or 446 or 449
451 430 or 432 or 438 or 443
452 451 not 450
453 exp Child/
454 exp pediatrics/
455 child*.ti,ab.
456 exp infant/
457 infant*.ti,ab.
458 (baby or babies).ti,ab.
459 "adolescent"/ or adolescence*.ti,ab.
460 (pediatric*1 or paediatric*1).ti,ab.
461 (neonat* or newborn*).ti,ab.
462 453 or 454 or 455 or 456 or 457 or 458 or 459 or 460 or 461
463 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53
464 36 or 37 or 38
465 105 or 106 or 107 or 173 or 201 or 282 or 407 or 463
466 5 or 11 or 19 or 29 or 35
467 464 and 465
468 452 and 466 and 467
469 468 not 462
### Supplementary Material 2. List of excluded studies

<table>
<thead>
<tr>
<th>Studies</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migliore A. Clin Med Insights Arthritis Musculoskelet Disord.2010;3:55-68</td>
<td></td>
</tr>
<tr>
<td>Helliwell PS. J Rheumatol. 2006;33(7):1439-41</td>
<td></td>
</tr>
<tr>
<td>Kresnik E, et al. Nucl Med Commun. 2002;23(7):683-8</td>
<td>Wrong inclusion criteria</td>
</tr>
</tbody>
</table>